Heron Therapeutics (NASDAQ:HRTX) Posts Quarterly Earnings Results, Meets Estimates

Heron Therapeutics (NASDAQ:HRTX) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03), Zacks reports. The company had revenue of $32.81 million for the quarter, compared to analyst estimates of $36.40 million. During the same period in the prior year, the firm posted ($0.17) earnings per share. Heron Therapeutics updated its Q4 2024 guidance to EPS and its FY 2024 guidance to EPS.

Heron Therapeutics Stock Up 0.8 %

HRTX stock opened at $1.22 on Thursday. The business has a 50 day moving average price of $1.85 and a 200 day moving average price of $2.53. The stock has a market cap of $185.04 million, a price-to-earnings ratio of -6.72 and a beta of 1.81. Heron Therapeutics has a fifty-two week low of $0.72 and a fifty-two week high of $3.93.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on HRTX shares. Needham & Company LLC decreased their price target on shares of Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Wednesday. StockNews.com upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.